ovarian androgen generation: Increased peripheral 5 alpha-reductase activity in women with polycystic ovary syndrome. J Clin Endocrinol Metab 2003;88:2760–2766.
53Vassiliadi DA, Barber TM, Hughes BA, McCarthy MI, Wass JA, Franks S, et al: Increased 5 alpha-reductase activity and adrenocortical drive in women with polycystic ovary syndrome. J Clin Endocrinol Metab 2009;94:3558–366.
54Vandenput L, Mellström D, Lorentzon M, Swanson C, Karlsson MK, Brandberg J, et al: Androgens and glucuronidated androgen metabolites are associated with metabolic risk factors in men. J Clin Endocrinol Metab 2007;92:4130–4137.
55Hemsell DL, Grodin JM, Brenner PF, Siiteri PK, MacDonald PC: Plasma precursors of estrogen. II. Correlation of the extent of conversion of plasma androstenedione to estrone with age. J Clin Endocrinol Metab 1974;38:476–479.
56Eyster KM: The estrogen receptors: an overview from different perspectives. Methods Mol Biol 2016;1366:1–10.
57Simpson ER: Role of aromatase in sex steroid action. J Mol Endocrinol 2000;25:149–156.
58Deslyper JP, Verdonck L, Vermeulen: A Fat tissue: a steroid reservoir and site of steroid metabolism. J Clin Endocrinol Met 1985;61:564–571.
59Sxymczak J, Millewicz A, Thijssen JHH, Blankstein MA, Daroszewski J: Concentration of sex steroids in adipose tissue after menopause. Steroids 1998;62:319–321.
60Blouin K, Richard C, Brochu G, Hould FS, Lebel S, Marceau S, et al: Androgen inactivation and steroid-converting enzyme expression in abdominal adipose tissue in men. J Endocrinol 2006;191:637–649.
61World Health Organization (WHO). Obesity and Overweight. Fact sheet 2016 . Geneva, WHO, 2016. http://www.who.int/mediacentre/factsheets/fs311/en/.
62Eriksson J, Haring R, Grarup N, Vandenput L, Wallaschofski H, Lorentzen E, et al: Causal relationship between obesity and serum testosterone status in men: a bi-directional mendelian randomization analysis. PLoS One 2017;12:e0176277.
63De Maddalena C, Vodo S, Petroni A, Aloisi AM: Impact of testosterone on body fat composition. J Cell Physiol 2012;227:3744–3748.
64Michalakis K, Mintziori G, Kaprara A, Tarlatzis BC, Goulis DG: The complex interaction between obesity, metabolic syndrome and reproductive axis: a narrative review. Metabolism 2013;62:457–478.
65Morelli A, Sarchielli E, Comeglio P, Filippi S, Vignozzi L, Marini M, et al: Metabolic syndrome induces inflammation and impairs gonadotropin-releasing hormone neurons in the preoptic area of the hypothalamus in rabbits. Mol Cell Endocrinol 2014;382:107–119.
66Sarchielli E, Comeglio P, Squecco R, Ballerini L, Mello T, Guarnieri G, et al: Tumor necrosis factor-α impairs kisspeptin signaling in human gonadotropin-releasing hormone primary neurons. J Clin Endocrinol Metab 2017;102:46–56.
67Garvey WT, Mechanick JI, Brett EM, Garber AJ, Hurley DL, Jastreboff AM, et al: American association of Clinical Endocrinologists and American College of Endocrinology Comprehensive Clinical Practice guidelines for medical care of patients with obesity executive summarycomplete guidelines available at https://www.aace.com/publications/guidelines. Endocr Pract 2016;22:842–884.
68Camacho EM, Huhtaniemi IT, O’Neill TW, Finn JD, Pye SR, Lee DM, et al: Age-associated changes in hypothalamic-pituitary-testicular function in middle-aged and older men are modified by weight change and lifestyle factors: longitudinal results from the European Male Ageing Study. Eur J Endocrinol 2013;168:445–455.
69Corona G, Rastrelli G, Monami M, Saad F, Luconi M, Lucchese M, et al: Body weight loss reverts obesity-associated hypogonadotropic hypogonadism: a systematic review and meta-analysis. Eur J Endocrinol 2013;168:829–843.
70Bhasin S, Cunningham GR, Hayes FJ, Matsumoto AM, Snyder PJ, Swerdloff RS, et al: Testosterone therapy in men with androgen deficiency syndromes: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab 2010;95:2536–2559.
71Haider A, Yassin A, Doros G, Traish AM, Saad F: Reductions of weight and waist size in 362 hypogonadal men with obesity grades I to III under long-term treatment with testosterone undecanoate (TU): observational data from two registry studies. Endocr Rev 2014;35:21–24.
72Corona G, Giagulli VA, Maseroli E, Vignozzi L, Aversa A, Zitzmann M, et al: Testosterone supplementation and body composition: results from a meta-analysis of observational studies. J Endocrinol Invest 2016;39:967–981.
73Corona G, Giagulli VA, Maseroli E, Vignozzi L, Aversa A, Zitzmann M, et al: Therapy of endocrine disease: testosterone supplementation and body composition: results from a meta-analysis study. Eur J Endocrinol 2016;174:R99–R116.
74Traish AM: Testosterone and weight loss: the evidence. Curr Opin Endocrinol Diabetes Obes 2014;21:313–322.
75Zurlo F, Larson K, Bogardus C, Ravussin E: Skeletal muscle metabolism is a major determinant of resting energy expenditure. J Clin Invest 1990;86:1423–1427.
76Travison TG, Basaria S, Storer TW, Jette AM, Miciek R, Farwell WR, et al: Clinical meaningfulness of the changes in muscle performance and physical function associated with testosterone administration in older men with mobility limitation. J Gerontol A Biol Sci Med Sci 2011;66:1090–1099.
77NCT02672592. Effects of Interleukin-1 Beta on Low Testosterone Levels in Men with Obesity and Metabolic Syndrome (TestIL). https://clinicaltrials.gov/ct2/show/NCT02672592.
78Pelusi C, Giagulli VA, Baccini M, Fanelli F, Mezzullo M, Fazzini A, et al: Clomiphene citrate effect in obese men with low serum testosterone treated with metformin due to dysmetabolic disorders: a randomized, double-blind, placebo-controlled study. PLoS One 2017;12:e0183369.
79Bojesen A, Høst C, Gravholt CH: Klinefelter’s syndrome, type 2 diabetes and the metabolic syndrome: the impact of body composition. Mol Hum Reprod 2010;16:396–401.
80Calogero